Excessive inflammation and failed resolution of the inflammatory responses are underlying components of numerous conditions such as arthritis, cardiovascular disease, and cancer. Unfortunately, controlled delivery of the inflammation-resolving therapeutics to lesions is challenging. Thus, we design novel nanoformulations capable of carrying the inflammation-resolving therapeutic drugs to the inflammatory lesions efficiently, and demonstrate their therapeutic efficacy and pro-resolving potential in diverse animal models. This technology provides a step closer to the development of novel therapeutic nanoplatforms for inflammatory disease treatment.
- Kamaly N, Fredman G, Fojas JJ, Subramanian M, Choi WI, Zepeda K, Vilos C, Yu M, Gadde S, Wu J, Milton J, Carvalho Leitao R, Rosa Fernandes L, Hasan M, Gao H, Nguyen V, Harris J, Tabas I, Farokhzad OC. Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano. (2016 ) Apr 28. Full Text
- Gabrielle Fredman, Nazila Kamaly, Stefano Spolitu, Jaclyn Milton, Devram Ghorpade, Raymond Chiasson, George Kuriakose, Mauro Perretti, Omid Farokzhad and Ira Tabas, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Science Translational Medicine, 7(2015) 275ra20. Full Text
- Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Fayad ZA, Langer R, Tabas I, Farokhzad OC. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A, 10(2013) 6506. Full Text